NVG, LLC

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $80,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare coverage of Anti-Obesity Medicines.

Health Issues

Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.